Arbutus Biopharma Corporation

NASDAQ:ABUS

Biotechnology

Healthcare
$4.11 +1.13%

+$0.05 today

Market cap
$630.03M
Beta
0.63
P/E (TTM)
5.4
EPS (TTM)
$0.83
52W Low $3.04High $5.10

Volume 2.90M

Average 1.76M

ABUS Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Arbutus Biopharma CorporationNASDAQ: ABUS

Operating Margin · Q1 FY2026 · quarter ended Mar 2026

Operating margin widens to 94.4%

Operating margin was 94.4% in Q1 FY2026, up 2059.2 pp from a year earlier. On a trailing-twelve-month basis it was 80.8%, up 1511.6 pp year over year. Over 3 fiscal years it narrowed by 24.3 pp.

Context

  • Operating margin widened in 1 of the last 3 fiscal years.

What to watch

Whether operating margin reaches the consensus estimate from 1 analysts of 98.6% for the fiscal year ending Dec 2026, up from -192.1% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
94.4%+821.7 pp QoQ
Last fiscal yearDec 2025
-192.1%+1044.7 pp YoY
LTMMar 2026
80.8%+1511.6 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+2059.2 pp-581.7 pp-2640.8 pp
1 year+1044.7 pp+290.7 pp-753.9 pp
3 years-24.3 pp+144.6 pp+168.9 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-192.1%
Year-over-year change
+1044.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How ABUS compares with its peers on the latest reported figures

  • ABUS's LTM Mar 2026 operating margin of 80.8% is the highest of the 7 companies compared; the peer median is -122.1%.
  • Its year-over-year change of +1511.6 pp is the 2nd highest of 6, against a peer median of +71.2 pp.
  • Over three fiscal years its change of -24.3 pp compares with a peer median of -71.7 pp.
ABUS Competitors Peer median
Operating Margin for ABUS and competitors
Company Period LTM level YoY 3-year change
ABUSArbutus Biopharma CorporationLTM Mar 202680.8% +1511.6 pp-24.3 pp
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 202620.8% +28.1 pp+89.2 pp
ASMBAssembly Biosciences, Inc.LTM Mar 2026-19.1% +119.8 pp—
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026-87.2% +71.2 pp+13.1 pp
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026-156.9% -168.7 pp-71.7 pp
VIRVir Biotechnology, Inc.LTM Mar 2026-704.9% +2394.8 pp-734.2 pp
SLNSilence Therapeutics plcLTM Mar 2026-9396.6% —-15774.1 pp
AVIRAtea Pharmaceuticals, Inc.FY2025— ——
BNTCBenitec Biopharma Inc.FY2025— ——
Peer median (excluding ABUS) -122.1%+71.2 pp-71.7 pp

Competitors are the stored peer set for ABUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.99M39.02M18.14M6.17M14.08M
Cost of Revenue0000363K
Gross Profit10.99M39.02M18.14M6.17M13.72M
Gross Margin100.0%100.0%100.0%100.0%97.4%
Research & Development65.5M84.41M73.7M54.04M25.24M
Selling, General & Admin17.14M17.83M22.48M22.11M15.89M
Operating Expenses84.51M104.48M96.24M82.49M40.77M
Depreciation & Amortization1.75M1.43M1.4M1.38M363K
EBITDA(71.64M)(61.86M)(70.99M)(68.4M)(33.04M)
EBITDA Margin-652.0%-158.5%-391.3%-1108.5%-234.6%
Operating Income(73.52M)(65.46M)(78.1M)(76.32M)(27.05M)
Operating Margin-669.1%-167.8%-430.5%-1236.7%-192.1%
Interest Income127K2.19M5.69M6.59M4.07M
Interest Expense2.86M1.73M459K137K97K
Other Income / Expenses(2.73M)444K5.25M6.4M(6.45M)
Income Before Tax(76.25M)(65.01M)(72.85M)(69.92M)(33.5M)
Pre-Tax Margin-693.9%-166.6%-401.6%-1133.0%-237.9%
Income Tax Expense04.44M000
Net Income(76.25M)(69.46M)(72.85M)(69.92M)(33.5M)
Net Margin-693.9%-178.0%-401.6%-1133.0%-237.9%
EPS (Basic)(0.73)(0.46)(0.44)(0.38)(0.17)
EPS (Diluted)(0.73)(0.46)(0.44)(0.38)(0.17)
Weighted Avg Shares106.24M150.94M165.96M185.61M191.6M
Weighted Avg Shares (Diluted)106.24M150.94M165.96M185.61M191.6M

Arbutus Biopharma Corporation

NASDAQ:ABUS

Intrinsic Alpha fair value

Locked

Current Price

$4.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.